MGAT5

Across TCGA pan-cancer cohorts, MGAT5 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MGAT5 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher MGAT5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MGAT5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, SKCM, and ESCA are the cancer types where MGAT5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.471	0.904	<.001	34	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	20	view →
ESCA	OS	Median	All	0.198	0.872	.003	18	view →
LUAD	OS	Median	II,III,IV	0.248	0.680	.019	12	view →
UCS	DFS	Median	All	0.132	0.530	.041	6	view →
HNSC	OS	Median	IV	0.057	0.733	<.001	6	view →
UCEC	DFS	Median	All	0.948	0.829	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MGAT5–BRCA (DFS)

Open the BRCA breakdown →